A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

Summary

The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Metabolic Dysfunction-Associated Steatohepatitis
• Non-alcoholic Fatty Liver Disease

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 75 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

GlaxoSmithKline

Last updated on ClinicalTrials.gov

July 8, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites